Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
详细信息 查看全文
- 作者：Stefan Sturm ; Anton Forsberg ; Stephane Nave…
- 关键词：Monoamine oxidase inhibitor ; MAO ; B ; Sembragiline ; Alzheimer’s disease ; Positron emission tomography
- 刊名：European Journal of Nuclear Medicine and Molecular Imaging
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：44
- 期：3
- 页码：382-391
- 全文大小：785KB
- 刊物类别：Medicine
- 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1619-7089
- 卷排序：44
文摘
PurposeIn Alzheimer’s disease (AD), increased metabolism of monoamines by monoamine oxidase type B (MAO-B) leads to the production of toxic reactive oxygen species (ROS), which are thought to contribute to disease pathogenesis. Inhibition of the MAO-B enzyme may restore brain levels of monoaminergic neurotransmitters, reduce the formation of toxic ROS and reduce neuroinflammation (reactive astrocytosis), potentially leading to neuroprotection. Sembragiline (also referred as RO4602522, RG1577 and EVT 302 in previous communications) is a potent, selective and reversible inhibitor of MAO-B developed as a potential treatment for AD.